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Valorization
Knowledge valorization refers to “the process of creating value from knowledge 
by making  knowledge suitable and/or available for economic and/or societal use 
and translating that knowledge into competitive products, services, processes and 
entrepreneurial activity.” 
(National Valorization Commission 2013)
In other words: the creation of societal and economic value from scientific knowledge. 
Examples include developing a product or a medicine, or applying scientific knowledge 
to a system or process. In fact, public investments into science should generate returns 
that benefit the economy. It is a strategy that brings science closer to society. The term 
‘knowledge valorization’ is akin to the term ‘innovation’. Innovation means converting 
inventions to reality, thereby applying them to a product or process. An invention alone 
is not considered an innovation; innovation only applies if the invention is used in 
practice. At Maastricht University, the Maastricht Valorization Center (MVC) provides 
support to researchers, students and businesses in promoting knowledge valorization.
For knowledge utilization, it is necessary that knowledge can be used outside the 
laboratory; that there is market potential and interest from investors. The studies 
presented in this thesis were funded by Top Institute Food and Nutrition (TIFN), a 
public-private partnership on pre-competitive research in food and nutrition. As such, 
TIFN provided the linking pin between the university and the marketplace. It brought 
together the supply of knowledge from the university and the demand for knowledge 
from the marketplace. Experts of international food industries, clinicians, and health 
care professionals collaborated with the researchers in this project, referred to as the 
Gastrointestinal Health project ‘microbiota, metabolism and energy harvesting’. During 
frequent meetings, these partners helped the researchers continue to develop their 
knowledge through direct interaction and exchange of relevant knowledge from their 
side. This collaboration led to demand-driven research that, in turn, gave the nutritional 
industry insight into the major role the gut microbiota may play in tackling worldwide 
obesity. A major global societal objective is after all the reduction of obesity and science 
is expected to have a crucial role in achieving this goal.
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Obesity is a major epidemiologic challenge facing today’s doctors, with an ever 
increasing annual allocation of healthcare resources for the disease and related 
comorbidities. Worldwide, obesity has nearly tripled since 1975. In 2016, 39% of adults 
aged 18 years and over were overweight, and 13% were obese. More concerning than 
the rise in obesity among adults is the increased prevalence of obesity among children. 
Over 40 million children under the age of 5 were overweight or obese in 2016. While 
obesity is clearly a major public health issue, obesity and being overweight turned out 
to be among the top 10 of leading causes of global mortality and burden of disease. 
The overall morbidity seen in this growing patient population remains a key issue 
contributing to decreased quality of life. Impairment in activities of daily living such as 
eating, dressing, and transferring to and from a bed or wheelchair occur at a younger age 
in obese patients compared to non-obese controls. If overall mortality decreases but the 
diagnosis and treatment of obesity-related conditions continue to increase, the cost of 
managing the obese patient population could be overwhelming. As such, obesity inflicts 
a tremendous economic burden on health care systems.
The leading cause of obesity and overweight is an energy imbalance between calories 
consumed and calories expended. Importantly, several studies over the last decades have 
recognized the gut microbiota as an additional factor contributing to this obesity crisis. 
However, the understanding regarding which microbes are ‘beneficial’ and how these 
microbes interact with host metabolism, especially in humans, have remained unclear 
and require thorough investigation. Therefore, the overall aim of this research thesis was 
to elucidate the role of the gut microbiota in human substrate and energy metabolism by 
combining a detailed characterization of gut microbiota composition and functionality 
with measurements of interorgan SCFA trafficking. SCFA were identified as important 
metabolites in the crosstalk between the gut microbiota and host.
A highly promising intervention for preventing or treating metabolic diseases including 
obesity and type 2 diabetes would therefore be a change in the gut microbiota 
composition and function. As a proof-of-concept, in this thesis antibiotics were used to 
temporarily modulate the gut microbiota composition in a robust way, and the effects 
on insulin sensitivity, energy and substrate metabolism were examined. 57 obese men 
with impaired insulin resistance were orally treated with 1500mg/day amoxicillin, 
vancomycin, or placebo for 7 days. Although vancomycin treatment decreased microbial 
diversity, no significant impact of antibiotic treatment on insulin sensitivity, energy and 
substrate metabolism was found. At 8 weeks follow-up, gut microbial composition was 
still considerably altered as compared to baseline. This finding once again indicates the 
importance of research into the effects antibiotics have on gut microbiota composition 
and function considering that antibiotics are widely used in clinical settings. Important 
here is to take into account that the extent to which antibiotics may affect the gut 
microbiota composition is highly variable between persons. As diet is an important 
factor shaping the gut microbiome, the impact of antibiotics might be related to a 
person’s dietary habits as well. A patient-specific diet-induced manipulation of the gut 
microbiota targeting specific microbial responses seems an important aspect for future 
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research to tackle obesity and related quality of life and healthcare costs. Research into 
prebiotics, for example, might be an effective way to alter host metabolism in obese 
insulin resistant subjects when applied at the individual rather than on a population 
level.
Prebiotics already received considerable attention because of their potential to 
beneficially affect gut health. Given the growing interest in exploring the best location 
of administration of prebiotics, the interorgan exchange of the microbial fermentation 
products of prebiotics was determined in men. These studies revealed that the exchange 
of SCFA and amino acids differs in the proximal colon versus the distal colon. Whereas 
amino acids were predominantly released by the proximal colon, SCFA were mainly 
released by the distal colon. This may reflect the fact that a larger part of absorbed 
SCFA are metabolized by the intestinal mucosa of the proximal colon. Indeed, the 
SCFA receptors GPR41 and 43 are mainly expressed in the ileum and the proximal 
colon. With respect to the minor amino acid exchange in the distal colon, it may be 
possible that the remaining amino acids have been utilized by the gut microbiota to 
produce SCFA contributing to the high SCFA exchange in the distal colon. Finally, the 
liver showed a significant uptake of all SCFA. Hence, no intestinally produced SCFA 
escaped the splanchnic area indicating efficient hepatic metabolic clearance of SCFA. 
The clinical relevance of these findings needs to be further investigated as this unique 
human model may make it possible to study the influence of manipulating amino acid 
and/or SCFA availability in the intestines (using pre- and/or pro-biotics) in order to elicit 
beneficial effects on human substrate and energy metabolism and glucose homeostasis. 
Larger patient groups and additional metabolic diseases have to be investigated, i.e. 
insulin sensitive versus insulin resistant patients. However, the differences in microbial 
composition at baseline could have influenced fermentation rates and the production 
of amino acids and/or SCFA. Therefore, it is advisable to take feces samples in future 
studies to determine fecal amino acids and/or SCFA concentrations next to plasma 
amino acid and SCFA concentrations. In this way, clinicians and dieticians in the field 
of obesity can contribute to personalized care by screening the microbiota profile in 
combination with the metabolic phenotype before designing a weight-loss program or 
dietary intervention. 
Overall, this research thesis may have benefits for the food industry as well. The findings 
have implications for the development of slowly fermentable fibers that increase SCFA 
specifically in the distal intestines given the higher SCFA release by the distal intestines. 
Using this information, food industry may want to optimize their existing product 
formulations. Several studies increasingly demonstrated that targeted SCFA delivery 
in the human colon exerts beneficial effects on energy and substrate metabolism. In 
addition, replacing digestible fibers with fermentable fibers attenuates the rise in blood 
glucose after a meal. However, various categories of prebiotic dietary fibers show 
different health benefits. The traditional prebiotics of fructo-oligosaccharides (FOS), 
inulin, and galacto-oligosaccharides (GOS) still provide the most evidence of beneficial 
health effects due to their fermentation, but many other categories of compounds may 
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be as effective as, or more effective than, the traditional prebiotics. Moreover, it may 
be of interest to investigate what potential effects these prebiotics have on microbial 
amino acid metabolism. In fact, the end-products of protein fermentation in the distal 
colon have well-established detrimental effects on the colonic microenvironment 
and epithelial health. Studies revealed that some of the metabolites from amino acid 
catabolism by bacteria might increase the risk of developing colon cancer. Gaseous 
compounds (hydrogen sulfide and nitric oxide), ammonia and phenols for example 
exert structural damage to the colonic mucus layer stimulating the synthesis of pro-
inflammatory cytokines. As such, increasing the delivery of fermentable fibers to the 
colon to shift bacterial activity away from protein fermentation on top of stimulating the 
SCFA production, should become an additional target in the design of any intervention. 
Since different fermentable fibers differentially influence fermentation activity, 
modifying total protein intake and the type of amino acids consumed should be taken 
into account as well. With respect to the minor amino acid exchange that we observed 
in the distal colon, it may be possible that part of the remaining amino acids have been 
utilized by the gut microbiota to produce SCFA, indirectly contributing to the beneficial 
high SCFA exchange in the distal colon. Thus, stimulating SCFA production by shaping 
the diversity of amino acid fermenting bacterial communities in the distal colon would 
mean double profit. Hence, these results are also very important to food manufacturers 
that target the sports nutrition and active adult markets that feature protein as a key 
ingredient. Collectively, this work will lead to development of new concepts for the 
formulation and management of foods to improve the well-being of humans and bacteria.
